A U.S. Food and Drug Administration (FDA) advisory panel voted unanimously Friday to authorize Pfizer (PFE)/BioNTech's (BNTX) third dose for Americans 65 and older, and for those with high risk of contracting a severe case of COVID-19.
The vote was the second of the afternoon, after a vote to support full approval for ages 16 and up to receive a booster dose. The new vote also entailed an emergency use authorization, rather than a supplemental approval of the already fully licensed vaccine.
A CDC advisory panel meeting, slated for next week, will delve further into who will qualify for the additional dose.$Pfizer(PFE)$ $BioNTech SE(BNTX)$
精彩评论